By Sheeba M. | May 31, 2026
Federal Rescheduling Odds Hit 60%—What It Means for MSO Valuations Now
The probability of federal cannabis rescheduling before the 2026 midterm elections has moved from “possible” to “likely.” Hill insiders pegging odds at 60%+ based on bipartisan sponsor counts and committee momentum. For investors, this isn’t a binary event—it’s a repricing cascade.
The Cash Flow Revolution: Section 280E is the invisible hand squeezing MSO profitability. This IRS rule denies cost-of-goods deductions for businesses trafficking in Schedule I/II drugs, forcing MSOs to pay federal tax on gross margins (not net income). Result: 26-37% effective tax rates on EBITDA for large operators versus 21% for compliant businesses.
Federal rescheduling to Schedule III unlocks this immediately. Back-of-napkin math: a $100M EBITDA operator paying 35% tax effective rate versus 21% faces a $14M annual headwind. Rescheduling erases it. That’s $140-200M in valuation uplift at 10-15x EBITDA multiples.
The Institutional Capital Wave: Rescheduling also cracks open institutional capital markets. Pension funds, mutual funds, and hedge funds are currently blocked from cannabis holdings by their charters. Remove Schedule I/II status, and suddenly $500B+ in institutional dry powder becomes addressable. Curaleaf and Trulieve could access public debt and equity markets at near-investment-grade rates.
Who Wins First: MSOs with clean state footprints (California, Colorado, Massachusetts) and zero federal exposure face the smoothest transition. Trulieve’s Florida-heavy footprint is risk—if federal legalization triggers state-level regulatory purges in key markets, consolidation accelerates. Curaleaf’s multi-state diversification actually becomes a hedge.
Insider Timing Signal: Watch for Board buyback authorizations and executive option exercises to spike in Q2/Q3. Management teams pricing in rescheduling odds are repositioning capital to maximize shareholder upside. Early exercise of in-the-money options before a reclassification event is textbook insider positioning.
Key Tickers to Track
- TRUL — Trulieve (largest MSO, most exposed to 280E benefit)
- CURLF — Curaleaf (diversified state footprint, institutional-grade balance sheet target)
- AYRWF — Ayr Wellness (regional consolidation play post-rescheduling)
- VERANO — Verano Holdings (West Coast footprint, institutional ready)
Sources
- Congress.gov — Track cannabis rescheduling bills and sponsor updates
- IRS Publication 535 — Section 280E detailed guidance and exclusions
- Politico — Capitol Hill cannabis policy tracking and legislative momentum
Track cannabis stocks with the Weedstock Real-Time Tracker